Bilayer Effects of Antimalarial Compounds.

Area of Science:

• Medicinal Chemistry
• Biophysics
• Drug Discovery

Background:

• Antimalarial drug resistance is a persistent challenge, driving the need for novel therapeutic agents.
• The Medicines for Malaria Venture (MMV) developed the Malaria Box, a collection of compounds to accelerate drug development.
• Assessing compound toxicity early in the drug development pipeline is crucial for identifying viable drug candidates.

Purpose of the Study:

• To evaluate the membrane-perturbing effects of potent Malaria Box compounds.
• To identify compounds that may cause toxicity through bilayer interactions.
• To assess the utility of membrane perturbation assays in predicting compound safety.

Main Methods:

• Utilized a gramicidin-based stopped-flow fluorescence assay to measure bilayer-mediated effects.
• Tested 80 potent compounds from the Malaria Box.
• Analyzed compounds for alterations in membrane protein conformational changes.

Main Results:

• Four out of 80 tested compounds demonstrated significant alterations in membrane properties (p < 0.05).
• Compound MMV007384 exhibited potent bilayer-perturbing activity.
• MMV007384 is known to be toxic in various cell-based assays, correlating with its membrane-disrupting effects.

Conclusions:

• Membrane perturbation assays can serve as an indicator for potential compound toxicity.
• MMV007384, a potent bilayer-perturbing agent, warrants caution due to its likely toxicity.
• Early identification of membrane-active compounds can aid in the selection of safer drug candidates for malaria treatment.